BiotechTube
Curileum Discovery

Curileum Discovery

Cambridge, United Kingdom· Est.
curileum.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Curileum Discovery is a preclinical-stage biotech targeting gastrointestinal diseases, specifically colorectal cancer prevention and IBD treatment, through tissue regeneration. Its core asset is ULI262, a novel pan-PPAR agonist small molecule drug aimed at preventing polyp formation in high-risk patients, such as those with Familial Adenomatous Polyposis (FAP). The company is strategically located adjacent to St Mark's Hospital in London and is raising $20 million to fund a first-in-human clinical study in FAP patients starting in 2027. Backed by over 40 years of drug discovery expertise from its founder, Curileum leverages academic and industrial partnerships to advance its pipeline.

GastrointestinalOncology

Technology Platform

Small molecule pan-PPAR agonist platform targeting cell fate and tissue regeneration in the gastrointestinal epithelium.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

Success in the orphan indication of FAP provides a clear regulatory pathway and proof-of-concept for expanding into the massive broader markets of sporadic colorectal cancer prevention and IBD treatment.
Orphan Drug Designation for FAP could expedite development and provide market exclusivity.

Risk Factors

High risk of failure in translating a novel, first-in-class mechanism from preclinical models to human efficacy and safety.
The company is dependent on raising $20M to reach the clinic, and any delay or shortfall jeopardizes its timeline.
Demonstrating sufficient clinical benefit to change the standard of care from surveillance/surgery is a commercial challenge.

Competitive Landscape

Direct competition in the pharmacological prevention of FAP is limited, but the broader fields of chemoprevention and GI regenerative medicine are active. Curileum's differentiation lies in its specific pan-PPAR agonist mechanism aimed at redirecting cell fate, a novel approach compared to anti-inflammatory or cytotoxic strategies.

More companies in Small Molecule Drugs →More companies in United Kingdom →